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98Mortality, Hospitalization, and Technique Failure in Daily Home
Hemodialysis and Matched Peritoneal Dialysis Patients:
A Matched Cohort Study
Eric D. Weinhandl, PhD,1 David T. Gilbertson, PhD,1 and Allan J. Collins, MD1,2
Background: Use of home dialysis is growing in the United States, but few direct comparisons of major
clinical outcomes on daily home hemodialysis (HHD) versus peritoneal dialysis (PD) exist.
Study Design: Matched cohort study.
Setting & Participants:We matched 4,201 new HHD patients in 2007 to 2010 with 4,201 new PD patients
from the US Renal Data System database.
Predictor: Daily HHD versus PD.
Outcomes: Relative mortality, hospitalization, and technique failure.
Results:Mean time from end-stage renal disease onset to home dialysis therapy initiation was 44.6 months
for HHD and 44.3 months for PD patients. In intention-to-treat analysis, HHD was associated with 20% lower
risk for all-cause mortality (HR, 0.80; 95% CI, 0.73-0.87), 8% lower risk for all-cause hospitalization (HR, 0.92;
95% CI, 0.89-0.95), and 37% lower risk for technique failure (HR, 0.63; 95% CI, 0.58-0.68), all relative to PD. In
the subset of 1,368 patients who initiated home dialysis therapy within 6 months of end-stage renal disease
onset, HHD was associated with similar risk for all-cause mortality (HR, 0.95; 95% CI, 0.80-1.13), similar
risk for all-cause hospitalization (HR, 0.96; 95% CI, 0.88-1.05), and 30% lower risk for technique failure
(HR, 0.70; 95% CI, 0.60-0.82). Regarding hospitalization, risk comparisons favored HHD for cardiovascular
disease and dialysis access infection and PD for bloodstream infection.
Limitations: Matching unlikely to reduce confounding attributable to unmeasured factors, including residual
kidney function; lack of data regarding dialysis frequency, duration, and dose in daily HHD patients and fre-
quency and solution in PD patients; diagnosis codes used to classify admissions.
Conclusions: These data suggest that relative to PD, daily HHD is associated with decreased mortality,
hospitalization, and technique failure. However, risks for mortality and hospitalization were similar with these
modalities in new dialysis patients. The interaction between modality and end-stage renal disease duration at
home dialysis therapy initiation should be investigated further.
Am J Kidney Dis. 67(1):98-110. ª 2016 The Authors. Published by Elsevier Inc. on behalf of the National
Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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oi.org/10.1053/j.ajkd.2015.07.014peritoneal dialysis (PD). The End-Stage Renal Disease
(ESRD) Networks reported increases in HHD and PD
patients from 7,208 to 7,811 (18.4%) and 38,279 to
42,146 (110.1%), respectively, between the ends of
2012 and 2013.1-17 In contrast, the number of in-center
hemodialysis patients grew by only 2.7% during 2013.
Unfortunately for physicians and patients who are
considering home dialysis, few comparisons of out-
comes with HHD versus PD exist.18-20 Comparisons of
outcomes with in-center hemodialysis versus PD21 are
irrelevant because HHD differs from in-center hemo-
dialysis not only in setting, but also in frequency.22
We compared clinical outcomes among daily HHD
patients and matched PD patients, 2006 to 2010.
Daily HHD patients initiated use of the NxStage
System One (NxStage Medical Inc) from 2007
through 2010. Matched PD patients were identiﬁed
from US Renal Data System (USRDS) records. Our
primary aim was to compare the risks for all-cause
mortality, all-cause admissions, and technique fail-
ure in daily HHD and matched PD patients.Am J Kidney Dis. 2016;67(1):98-110
Outcomes of Daily HHD Versus PDMETHODS
Study Cohort
Daily HHD patients were identiﬁed from a registry of NxStage
System One users maintained by NxStage Medical Inc. Each
registry record included beginning and ending dates of System
One use and the prescribed number of dialysis sessions per week.
Beginning dates ranged from January 1, 2007, to December 31,
2010. Almost all (95.9%) records were linked to patients in the
USRDS database. We retained the subset of daily HHD patients
described in Fig 1. The source cohort of PD patients comprised
those who initiated PD therapy during October 1, 2006, to
September 30, 2010, either for the ﬁrst time after ESRD onset or
after having discontinued PD therapy for at least one year, and
who either carried Medicare coverage during the 3 months pre-
ceding the date of PD therapy initiation or initiated PD therapy
within 6 months of ESRD onset.
We categorized all daily HHD patients into 3 strata: those with
ESRD duration of 6 months or longer on the date of home dialysis
therapy initiation, with Medicare during the 3 months preceding
the date of home dialysis therapy initiation (stratum 1); those with
ESRD duration less than 6 months on the date of home dialysis
therapy initiation, with Medicare during the 3 months preceding
the date of home dialysis therapy initiation (stratum 2); and those
with ESRD duration less than 6 months on the date of home
dialysis therapy initiation, without Medicare during the 3 months
preceding the date of home dialysis therapy initiation (stratum 3).
Data Elements
For each daily HHD or PD patient, we identiﬁed the applicable
ESRDNetwork and characteristics in Table 1. Age, ESRD duration,
ESRD Network, dual enrollment, Part D enrollment, low-income
subsidization, transplant waitlist registration, and provider afﬁlia-
tion were deﬁned at the date of home dialysis therapy initiation
(index date). Body mass index was ascertained from the ﬁnal
outpatient dialysis claim during the 3 months preceding the indexPaents in registry of NxStage System One users
n = 8308
Linked to USRDS database
n = 7965 (95.9%)
Iniated DHHD no later than June 30, 2010
n = 6571 (79.1%)
Prescribed 5 or 6 dialysis sessions per week
n = 6137 (73.9%)
Carried Medicare during 3 months 
preceding DHHD iniaon or iniated 
DHHD within 6 months of ESRD onset
n = 4460 (53.7%)
Matched to PD paent
n = 4201 (50.6%)
Figure 1. Sample size of study cohort, with iterative applica-
tion of inclusion criteria. Abbreviations: DHHD, daily home he-
modialysis; ESRD, end-stage renal disease; PD, peritoneal
dialysis; USRDS, US Renal Data System.
Am J Kidney Dis. 2016;67(1):98-110date, or in lieu of claims with body mass index data, from the ESRD
Medical Evidence Report. Hospitalization and intravenous drug
doses were ascertained from inpatient claims and outpatient dialysis
claims, respectively, during the 3 months preceding the index date.
Comorbid conditions were deﬁned from the Medical Evidence
Report and all claims during the 6 months preceding the index date;
we required one or moreMedicare Part A or 2 or more Part B claims
with relevant diagnosis codes to deﬁne conditions.23 Biomarkers
were ascertained from the Medical Evidence Report.
Regarding follow-up data, we ascertained dates of death, kidney
transplantation, cessation of PD therapy, and loss of Medicare
coverage from USRDS data. Cause of death was deﬁned from the
ESRD Death Notiﬁcation. Hospitalization dates were ascertained
from inpatient claims. We categorized the cause of each hospi-
talization into 1 of 4 categories: cardiovascular disease, infection,
dialysis access dysfunction unrelated to infection, or other cause.
Cardiovascular disease and infection were divided into 7 and 8
mutually exclusive types, respectively. Codes deﬁning hospitali-
zation causes and types are shown in Table S1 (provided as online
supplementary material).
Matching Algorithm
We used propensity score matching.24 For each stratum, we ﬁt a
logistic regression model of daily HHD therapy initiation in the
pooled set of daily HHD and PD patients. Predictors included
main effects for all characteristics in Table 1, ESRD Network, and
number of days between October 1, 2006, and the index date.
From the ﬁtted model, we calculated the logit of the probability of
daily HHD initiation therapy in each daily HHD or PD patient.
We ordered daily HHD patients by index date and arbitrarily
within index date and applied a greedy matching algorithm in the
speciﬁed order. For each daily HHD patient with propensity score
logit equal to r, we identiﬁed the index date, ESRD duration (d
months), Part D enrollment, and recent history of hospitalization.
We retained PD patients who initiated PD therapy within 3 months
of the index date, with ESRD duration between d 2 6 and d 1 6
months, and with the same values of the other mentioned factors.
From this subset, we selected the PD patient with propensity score
logit equal to s, such that the absolute difference between r and s
was minimized; however, we applied no caliper. If the subset was
empty, the daily HHD patient was excluded from analysis.
Statistical Analysis
We calculated mean summaries of measured factors in daily
HHD andmatched PD patients, overall and by stratum.We assessed
the match quality with absolute standardized differences;
differences , 10% indicate sufﬁcient similarity to obviate adjust-
ment.25 For follow-up, we used both intention-to-treat and on-
treatment rules. By the intention-to-treat rule, we followed up pa-
tients from the index date to the earliest of death, loss of Medicare
coverage (in analyses of hospitalization risk), and December 31,
2010. For the on-treatment rule, we added kidney transplantation
and the ﬁnal day of the ﬁrst 2-month interval of uninterrupted in-
center hemodialysis to the list of dates on which follow-up may end.
To compare risk for death between daily HHD and PD patients,
we calculated the cumulative incidence of death. In on-treatment
analysis, kidney transplantation and cessation of home dialysis
were classiﬁed as competing risks. In addition, we used Cox
proportional hazards regression to estimate relative hazards of all-
cause, cause-speciﬁc, and interval-speciﬁc death for daily HHD
versus PD. Each model included 3 strata, corresponding to the
mentioned strata deﬁned jointly by ESRD duration and Medicare
coverage, and stratum-speciﬁc adjustment for ESRD duration. To
compare risk for hospitalization between daily HHD and PD pa-
tients with Medicare, we used the Prentice-Williams-Peterson
conditional gap-time model to estimate relative hazards of all-
cause, cause-speciﬁc, and type-speciﬁc admission for daily HHD99
Table 1. Characteristics of Daily HHD Patients and Matched PD Patients
Characteristic
All Patients
ESRD Duration $ 6 mo and
Medicare
ESRD Duration , 6 mo and
Medicare
ESRD Duration , 6 mo and
No Medicare
Daily HHD PD ASDa Daily HHD PD Daily HHD PD Daily HHD PD
Sample size 4,201 4,201 2,833 2,833 468 468 900 900
Age,b y 53.8 6 14.9 54.6 6 15.0 5.6 52.66 15.0 53.8 6 15.2 64.9 6 13.3 64.3 6 13.5 51.9 6 12.7 52.1 6 13.0
Race
Black 24.4 25.8 3.1 28.9 31.2 12.4 12.2 16.8 15.8
Nonblack 75.6 74.2 3.1 71.1 68.8 87.6 87.8 83.2 84.2
Sex
Female 33.0 36.5 7.4 34.5 39.1 30.6 34.0 29.3 29.3
Male 67.0 63.5 7.4 65.5 60.9 69.4 66.0 70.7 70.7
Primary cause of ESRD
Diabetes 33.7 35.2 3.1 31.1 33.9 41.9 40.4 37.9 36.4
Hypertension 20.1 21.2 2.8 21.0 22.1 24.6 25.2 14.8 16.2
GN or cystic kidney disease 25.0 23.2 4.2 26.2 24.1 11.8 10.3 28.1 27.1
Other or unknown cause 21.2 20.4 1.9 21.7 19.9 21.7 24.1 19.2 20.3
ESRD duration,b mo 44.6 6 57.5 44.3 6 57.6 0.5 64.96 60.2 64.6 6 60.5 3.0 6 1.7 3.1 6 1.6 2.36 2.2 1.8 6 1.9
Dual Medicare/Medicaid
enrollmentb
24.9 25.7 1.8 32.6 33.0 16.7 17.1 5.1 7.2
Medicare Part D enrollmentb
Not enrolled 50.9 50.9 0.0 39.1 39.1 52.1 52.1 87.4 87.4
Enrolled without LIS 16.3 16.3 0.0 17.0 17.0 27.8 27.8 8.0 8.0
Enrolled with LIS 32.8 32.8 0.0 43.9 43.9 20.1 20.1 4.6 4.6
Comorbid conditionsc
Cardiovascular conditions
Cardiac disease, NOS 27.4 27.6 0.5 30.3 30.3 47.0 46.6 8.3 8.6
Cerebrovascular disease 8.0 9.1 3.9 8.5 9.7 12.8 15.0 3.7 4.1
Congestive heart failure 31.1 31.3 0.5 34.3 35.0 47.2 42.1 12.4 14.0
Hypertension 43.2 45.6 4.7 40.1 42.7 62.2 62.6
Ischemic heart disease 27.5 28.9 3.1 29.6 32.1 44.4 42.1 12.3 12.1
Peripheral arterial disease 21.2 22.7 3.6 24.4 26.4 31.8 30.8 5.8 6.8
Pulmonary heart disease 2.5 2.2 2.0 2.2 1.8 4.1 4.5
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Table 1 (Cont’d). Characteristics of Daily HHD Patients and Matched PD Patients
Characteristic
All Patients
ESRD Duration $ 6 mo and
Medicare
ESRD Duration , 6 mo and
Medicare
ESRD Duration , 6 mo and
No Medicare
Daily HHD PD ASDa Daily HHD PD Daily HHD PD Daily HHD PD
Noncardiovascular conditions
Cancer 10.0 8.7 4.3 9.6 8.2 17.3 16.2 7.3 6.3
Chronic pulmonary disease 13.1 13.5 1.2 11.8 12.6 20.9 19.2
Coagulopathy 6.7 5.9 3.1 6.2 5.6 9.2 7.5
Dementia or psychosis 3.0 3.1 0.7 3.0 3.0 3.2 3.9
Diabetes 47.7 48.9 2.5 47.0 49.2 60.3 58.3 43.3 43.1
Fluid or electrolyte disorders 44.4 40.1 8.7 43.0 38.2 52.8 52.1
Hemiplegia 0.9 1.2 2.7 0.6 0.9 2.8 2.8
HIV or AIDS 1.3 1.4 1.1 1.3 1.4 0.9 1.1
Iron deficiency anemia 84.6 81.4 8.4 85.6 81.6 78.0 79.9
Liver disease 4.0 3.6 2.2 4.0 3.7 3.9 2.6
Malnutrition 6.9 6.3 2.3 6.2 5.6 11.1 10.7
Body mass index,b kg/m2 29.3 6 7.5 29.0 6 7.3 4.0 28.9 6 7.4 28.6 6 7.1 29.5 6 7.6 29.1 6 7.1 30.5 6 7.8 30.3 6 7.9
Hospitalizationd
Any hospitalization 26.5 26.5 0.0 24.0 24.0 41.7 41.7
Mean cumulative hospitalized dayse 10.7 6 14.7 11.0 6 13.8 1.7 9.2 6 11.4 10.2 6 12.2 16.1 6 21.8 13.5 6 18.1
Kidney transplant waitlist registrationb 32.0 29.1 6.3 36.5 32.8 13.0 9.0 28.0 28.1
Serum albumin,f g/dL 3.5 6 0.7 3.5 6 0.7 0.2 3.4 6 0.7 3.4 6 0.7 3.56 0.7 3.5 6 0.7
Estimated GFR,f mL/min/1.73 m2 10.9 6 4.6 10.8 6 4.9 1.9 11.8 6 4.9 11.6 6 5.2 10.5 6 4.4 10.4 6 4.7
Hemoglobin,f g/dL 10.3 6 1.7 10.3 6 1.6 3.3 10.3 6 1.5 10.2 6 1.6 10.4 6 1.8 10.3 6 1.7
Affiliation of dialysis providerb
DaVita 45.6 43.1 5.0 46.5 41.9 43.2 42.3 44.0 47.4
Dialysis Clinic, Inc 1.3 1.6 2.4 1.5 1.9 0.2 0.2 1.1 1.2
Fresenius Medical Care 8.4 12.2 12.6 8.0 14.1 5.6 5.1 11.2 9.9
Small dialysis organization 13.1 12.7 1.1 13.3 12.6 14.3 13.7 12.0 12.7
Independent dialysis provider 19.8 17.7 5.2 20.2 17.9 22.2 25.2 17.2 13.4
Hospital-based dialysis provider 10.9 11.7 2.5 9.9 11.1 13.3 13.5 13.1 12.9
Unknown affiliation 0.9 1.0 0.3 0.6 0.5 1.2 0.0 1.4 2.5
Epoetin alfa exposured
Any exposure 81.7 79.5 5.4 82.9 79.3 74.4 80.8
Cumulative dose,g 1,000s IU 213.0 6 206.3 206.8 6 212.5 2.9 219.26 211.8 213.3 6 219.4 171.0 6 158.8 168.0 6 160.1
Darbepoetin alfa exposured
Any exposure 12.1 9.7 7.9 12.1 9.2 12.4 12.4
Cumulative dose,g mg 527.3 6 601.8 482.1 6 598.1 7.5 545.06 615.9 504.7 6 627.6 422.5 6 503.0 380.3 6 430.9
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Table 1 (Cont’d). Characteristics of Daily HHD Patients and Matched PD Patient
Characteristic
All Patients
ESRD Duration $ 6 mo and
Medicare
ESRD D ration , 6 mo and
Medicare
ESRD Duration , 6 mo and
No Medicare
Daily HHD PD ASDa Daily HHD PD Daily HH PD Daily HHD PD
IV iron exposured
Any exposure 72.7 69.5 7.1 72.9 68.7 71.6 74.6
Cumulative dose,g mg 795.36 626.0 845.56 553.9 8.5 769.1 6 600.0 819.6 6 527.4 956.2 6 74 .8 990.46 665.3
IV vitamin D sterol exposured
Any exposure 63.9 62.0 4.1 68.2 64.9 38.3 44.2
Cumulative dose,g mgh 137.46 108.5 145.26 113.1 7.0 142.5 6 110.1 152.2 6 115.0 82.9 6 68 83.2 6 68.5
Note: Unless otherwise indicated, values are given as percentage or mean 6 standard deviation. Missing values indicate either no pplicable factors (biochemistry at initiation of main-
tenance dialysis therapy in patients with ESRD duration $ 6 months) or unmeasured factors due to the absence of Medicare claims (com rbid conditions, hospitalization, and IV drug doses, in
non-Medicare patients). For All Patients column, values are derived by pooling strata with applicable factors.
Abbreviations: ASD, absolute standardized difference; ESRD, end-stage renal disease; GFR, glomerular filtration rate; GN, glome lonephritis; HHD, home hemodialysis; HIV, human
immunodeficiency virus; IV, intravenous; LIS, low-income subsidization; NOS, not otherwise specified; PD, peritoneal dialysis.
aDifference between daily HHD and matched PD patients, in percentage of 1 standard deviation.
bOn index date.
cDuring the 6 months preceding the index date or according to the Medical Evidence Report (for cardiac disease, NOS; cerebrovasc lar disease; congestive heart failure; ischemic heart
disease; peripheral arterial disease; cancer; and diabetes).
dDuring the 3 months preceding the index date.
eAmong hospitalized patients.
fAt initiation of maintenance dialysis therapy.
gAmong exposed patients.
hIn paricalcitol-equivalent units, with dose conversion ratios of 4.62 for calcitriol and 1.49 for doxercalciferol.
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Outcomes of Daily HHD Versus PDversus PD patients; we have previously described the rationale for
this model.22 Each model included the same strata and adjustment
that were speciﬁed for the mentioned Cox regression. Second, we
used Poisson regression to estimate relative rates of all-cause and
cause-speciﬁc hospital days for daily HHD versus PD. The model
included main effects for each of the 3 strata deﬁned jointly by
ESRD duration and Medicare coverage. To compare risk for
technique failure between daily HHD and PD patients, we calcu-
lated the cumulative incidence of technique failure. Death and
kidney transplantation were classiﬁed as competing risks. In
addition, we used Fine-Gray regression to estimate relative hazards
of technique failure for daily HHD versus PD. Each model
included the same strata and adjustment that were speciﬁed for the
mentioned Cox regression.
RESULTS
Descriptive Analysis
We identiﬁed 4,460 daily HHD patients; 1,006,
1,259, 1,393, and 802 patients initiated daily HHD
therapy in 2007, 2008, 2009, and the ﬁrst half of
2010, respectively. Of them, 3,092 (69.3%) patients
were Medicare beneﬁciaries who initiated daily HHD
therapy after 6 or more months since ESRD onset,
468 (10.5%) were Medicare beneﬁciaries who initi-
ated daily HHD therapy within 6 months of ESRD
onset, and 900 (20.2%) initiated daily HHD therapy
within 6 months of ESRD onset, but without Medi-
care coverage. Characteristics of daily HHD patients
and 46,411 contemporary PD patients are shown in
Table S2. Compared with PD patients, daily HHD
patients had a longer mean ESRD duration at home
dialysis therapy initiation and were more likely to be
registered on the kidney transplant waiting list.
For each of 4,201 (94.2%) daily HHD patients, we
identiﬁed 1 matched PD patient; mean ESRD duration
differentiated daily HHD patients with and without a
matched PD patient (Table S3). Characteristics of daily
HHD patients and matched PD patients are shown in
Table 1.Mean age of daily HHDpatients was 53.8 years
(PD patients, 54.6 years), 75.6% of daily HHD and
74.2% of PD patients were of nonblack race, and 67.0%
of dailyHHDand63.5%of PDpatientsweremen.Mean
ESRD duration at home dialysis therapy initiation was
44.6 months (44.3 months for PD patients). Matching
balanced measured factors (absolute standardized
difference, ,10%), except for dialysis at a Fresenius
Medical Care facility (daily HHD, 8.4%; PD, 12.2%).
Mortality
Cumulative incidence estimates of death for daily
HHD and matched PD patients are shown in Fig 2. In
intention-to-treat analysis of all patients, mortality esti-
mates for daily HHD versus PD were 6.2% versus 7.2%
at 6 months, 11.5% versus 14.7% at 1 year, 21.5%
versus 26.0% at 2 years, and 30.2% versus 35.6% at 3
years (Fig 2A), respectively. In contrast, in intention-to-
treat analysis of the subset of patients who initiated
home dialysis therapy within 6 months of ESRD onset,Am J Kidney Dis. 2016;67(1):98-110mortality estimates for daily HHD versus PD were 6.1%
versus 5.5% at 6 months, 10.9% versus 10.3% at 1 year,
20.3% versus 20.5% at 2 years, and 27.9% versus
32.2% at 3 years (Fig 2B). On-treatment analysis
revealed patterns of cumulative incidence similar to the
patterns in intention-to-treat analysis (Fig 2C and D).
Absolute rates and rate ratios (RRs) of death for
daily HHD and matched PD patients are shown in
Table 2. In intention-to-treat analysis of all patients,
mean follow-up duration for daily HHD versus PD
patients was 1.79 versus 1.65 years and corresponding
mortality rates were 12.1 and 15.1 deaths per 100
patient-years. The mortality hazard ratio (HR) was 0.80
(95% conﬁdence interval [CI], 0.73-0.87) for daily
HHD versus PD. Cause-speciﬁc mortality HRs were
0.81 for cardiovascular disease, 0.71 for infection, and
0.62 for cachexia or dialysis therapy withdrawal
(P, 0.01 for each). HRs varied little across follow-up
intervals. HRs from on-treatment analysis were similar.
In intention-to-treat analysis of the subset of patients
who initiated home dialysis therapy within 6 months of
ESRD onset, mortality rates for daily HHD versus PD
patients were 11.5 versus 11.8 deaths per 100 patient-
years. Themortality HRwas 0.95 (95%CI, 0.80-1.13).
Cause-speciﬁc mortality HRs were 0.87 for cardio-
vascular disease, 1.04 for infection, and 0.75 for
cachexia or dialysis therapy withdrawal; CIs for each
HR were wide. In interval analysis, mortality HRs
declined from 1.05 to 0.89 to 0.80 in follow-up years 1,
2, and 3 to 4, respectively, but the trend lacked sta-
tistical signiﬁcance (P 5 0.5). In on-treatment anal-
ysis, the mortality HR was 1.03 (95% CI, 0.85-1.26).
Hospitalization
Absolute rates and RRs of hospitalization for daily
HHD and matched PD patients were estimated in the
subset of 3,301 (78.6%) Medicare beneﬁciaries and
are shown in Table 3. In intention-to-treat analysis of
all patients, all-cause hospitalization rates for daily
HHD versus PD patients were 173.7 versus 199.0
admissions and 1,027.2 versus 1,266.9 days per 100
patient-years. The admission HR was 0.92 (95% CI,
0.89-0.95) and the hospital day RR was 0.81 (95% CI,
0.75-0.87). Cause-speciﬁc admission HRs were 0.85
for cardiovascular disease, 0.89 for infection, and
0.95 for dialysis access dysfunction unrelated to
infection; cardiovascular disease and infection asso-
ciations met statistical signiﬁcance, but dialysis access
dysfunction did not. Cause-speciﬁc hospital day RRs
were more pronounced. Admission HRs and hospital
day RRs in on-treatment analysis were similar.
In intention-to-treat analysis of the subset of pa-
tients who initiated home dialysis therapy within 6
months of ESRD onset, all-cause hospitalization rates
for daily HHD versus PD patients were 179.1 versus
187.2 admissions and 1,116.8 versus 1,212.2 days per103
0 1 2 3 4
0.0
0.
1
0.2
0.
3
0.4
0.
5
0.6
Follow−up time (years) Follow−up time (years)
Follow−up time (years) Follow−up time (years)
Cu
m
ul
at
ive
 in
cid
en
ce
 o
f d
ea
th
Cu
m
ul
at
ive
 in
cid
en
ce
 o
f d
ea
th
Cu
m
ul
at
ive
 in
cid
en
ce
 o
f d
ea
th
Cu
m
ul
at
ive
 in
cid
en
ce
 o
f d
ea
th
DHHD
PD
A
0 1 2 3 4
0.0
0.
1
0.2
0.
3
0.4
0.
5
0.6
DHHD
PD
B
0 1 2 3 4
0.0
0.
1
0.2
0.
3
0.4
0.
5
0.6
DHHD
PD
C
0 1 2 3 4
0.0
0.
1
0.2
0.
3
0.4
0.
5
0.6
DHHD
PD
D
Figure 2. Cumulative incidence estimates of death in intention-to-treat analysis of (A) all patients and (B) the subset with end-stage
renal disease (ESRD) duration less than 6 months on the index date and on-treatment analysis of (C) all patients and (D) the subset
with ESRD duration less than 6 months on the index date. Abbreviations: DHHD, daily home hemodialysis; PD, peritoneal dialysis.
Weinhandl, Gilbertson, and Collins100 patient-years. The admission HR was 0.96 (95%
CI, 0.88-1.05) and the hospital day RR was 0.91 (95%
CI, 0.75-1.11). Cause-speciﬁc admission HRs were
0.89 for cardiovascular disease, 1.01 for infection,
and 0.89 for dialysis access dysfunction unrelated to
infection, but with only 468 patients per group, no
associations were statistically signiﬁcant.
Type-speciﬁc admission HRs are shown in Table 4.
For admissions due to cardiovascular disease, HRs
favored daily HHD patients for diagnoses of cere-
brovascular disease; heart failure, ﬂuid overload, and
cardiomyopathy; hypertensive disease; and peripheral104arterial disease, with HRs between 0.63 and 0.82. For
admission due to infection, HRs favored daily HHD
for the diagnoses of dialysis access infection,
including peritonitis, and other infection. Conversely,
HRs favored PD patients for diagnoses of bacteremia
and sepsis and cardiac infection.
Technique Failure
Cumulative incidence estimates of technique fail-
ure for daily HHD and matched PD patients are
shown in Fig 3; failure was deﬁned by conversion to
in-center hemodialysis therapy for at least 2 months.Am J Kidney Dis. 2016;67(1):98-110
Table 2. Absolute Rates and RRs of Death for Daily HHD Patients in Intention-to-Treat and On-Treatment Analyses
All Patients ESRD Duration , 6 mo on Index Date
Daily HHD PD RRa (95% CI) P Daily HHD PD RRa (95% CI) P
Intention-to-treat
All-cause mortality 12.1 15.1 0.80 (0.73-0.87) ,0.001 11.5 11.8 0.95 (0.80-1.13) 0.6
Cause-specific mortality
Cardiovascular disease 5.0 6.2 0.81 (0.70-0.93) 0.002 4.4 4.9 0.87 (0.66-1.14) 0.3
Infection 1.5 2.1 0.71 (0.55-0.91) 0.006 1.5 1.4 1.04 (0.64-1.70) 0.9
Cachexia/dialysis withdrawal 1.4 2.1 0.62 (0.48-0.80) ,0.001 1.3 1.7 0.75 (0.46-1.21) 0.2
Other specified cause 1.9 1.9 1.04 (0.82-1.32) 0.8 2.0 1.6 1.27 (0.81-1.98) 0.3
Unknown cause 2.3 2.8 0.81 (0.66-1.00) 0.05 2.3 2.3 0.94 (0.64-1.39) 0.8
Interval-specific mortality
Year 1 12.3 15.7 0.78 (0.69-0.88) ,0.001 11.8 11.0 1.05 (0.83-1.32) 0.7
Year 2 12.0 14.5 0.81 (0.69-0.96) 0.01 11.2 12.2 0.89 (0.66-1.21) 0.5
Years 3-4 11.6 13.9 0.84 (0.68-1.04) 0.1 10.8 13.8 0.80 (0.53-1.20) 0.3
On-treatment
All-cause mortality 12.2 15.0 0.81 (0.73-0.90) ,0.001 12.1 11.4 1.03 (0.85-1.26) 0.8
Cause-specific mortality
Cardiovascular disease 5.3 6.4 0.83 (0.70-0.97) 0.02 5.0 5.2 0.93 (0.69-1.26) 0.6
Infection 1.6 2.1 0.71 (0.53-0.95) 0.02 1.7 1.2 1.40 (0.78-2.50) 0.3
Cachexia/dialysis withdrawal 1.3 1.9 0.68 (0.50-0.93) 0.02 1.5 1.5 0.95 (0.54-1.66) 0.8
Other specified cause 1.9 1.9 0.99 (0.75-1.32) 0.9 1.9 1.4 1.28 (0.74-2.22) 0.4
Unknown cause 2.2 2.7 0.78 (0.61-1.01) 0.06 2.0 2.1 0.92 (0.57-1.49) 0.7
Interval-specific mortality
Year 1 12.2 15.2 0.80 (0.70-0.91) ,0.001 11.9 10.6 1.10 (0.85-1.42) 0.5
Year 2 12.5 14.1 0.87 (0.70-1.07) 0.2 11.7 10.3 1.10 (0.74-1.64) 0.6
Years 3-4 11.4 16.0 0.73 (0.53-1.01) 0.05 14.2 19.8 0.68 (0.40-1.16) 0.2
Note: Referent: matched PD patients.
Abbreviations: CI, confidence interval; ESRD, end-stage renal disease; HHD, home hemodialysis; PD, peritoneal dialysis; RR, rate
ratio.
aHazard ratio from Cox proportional hazards regression.
Outcomes of Daily HHD Versus PDAmong all patients, estimates for daily HHD versus
PD were 9.2% versus 17.3% at 6 months, 18.0%
versus 27.1% at 1 year, 27.5% versus 37.0% at 2
years, and 32.1% versus 44.1% at 3 years (Fig 3A).
The HR of technique failure was 0.63 (95% CI, 0.58-
0.68) for daily HHD versus PD patients. Moreover,
among patients in the subset who initiated home
dialysis therapy within 6 months of ESRD onset, es-
timates for daily HHD versus PD were 8.3% versus
11.1% at 6 months, 16.0% versus 19.1% at 1 year,
24.7% versus 28.2% at 2 years, and 27.7% versus
37.5% at 3 years (Fig 3B). In this subset, the HR of
technique failure was 0.70 (95% CI, 0.60-0.82).
DISCUSSION
Direct comparison of outcomes with daily HHD
versus PD is not complicated by the potent con-
founding factors of capacity and desire for self-care
that is inherent in home dialysis and has compli-
cated previous comparisons of outcomes with either
daily HHD or PD versus in-center hemodialysis.
However, direct comparison is complicated by a dif-
ference in the usual time in the natural history of
ESRD that each modality is prescribed. In this study,
we compared risks for mortality, hospitalization, andAm J Kidney Dis. 2016;67(1):98-110technique failure in daily HHD patients and similar
PD patients who were identiﬁed by application of a
multistratum propensity score–matching algorithm.
We found that daily HHD patients had lower rates of
mortality and hospitalization than PD patients,
although the association was mostly conﬁned to those
who began home dialysis therapy after more than 6
months since ESRD onset. In the complement of
patients who began home dialysis therapy soon after
ESRD onset, mortality and hospitalization RRs were
near unity. However, the rate of technique failure was
signiﬁcantly lower for daily HHD versus PD patients,
regardless of ESRD duration.
Cardiovascular beneﬁts of intensive hemodialysis
have been reported. In meta-analysis, frequent or ex-
tended hemodialysis was associated with reductions in
left ventricular mass and blood pressure, decreased use of
antihypertensive medications, and increased left ven-
tricular ejection fraction.26 In the Frequent Hemodialysis
Network, 6 versus 3 in-center hemodialysis sessions per
week increased ventricular volumes.27 We previously
reported that daily HHD patients had signiﬁcantly lower
rates of hospitalization due to cardiovascular disease
generally and heart failure and hypertension speciﬁcally,
relative to matched in-center hemodialysis patients.22105
Table 3. Absolute Rates and RRs of Hospital Admissions and Days for Daily HHD Patients in Intention-to-Treat and
On-Treatment Analyses
All Patients ESRD Duration , 6 mo on Index Date
Daily HHD PD RRa (95% CI) P Daily HHD PD RRa (95% CI) P
Intention-to-treat
Admissions (per 100 patient-y)
All-cause 173.7 199.0 0.92 (0.89-0.95) ,0.001 179.1 187.2 0.96 (0.88-1.05) 0.4
Cause-specific
Cardiovascular disease 37.4 47.0 0.85 (0.80-0.91) ,0.001 38.6 45.6 0.89 (0.75-1.06) 0.2
Infection 50.4 59.6 0.89 (0.84-0.94) ,0.001 53.9 52.8 1.01 (0.87-1.18) 0.9
Dialysis access dysfunction 9.3 9.9 0.95 (0.84-1.08) 0.5 7.6 8.5 0.89 (0.60-1.30) 0.5
Other cause 76.6 82.5 0.94 (0.90-0.98) 0.008 78.9 80.4 0.97 (0.85-1.10) 0.6
Hospital days (per 100 patient-y)
All-cause 1,027.2 1,266.9 0.81 (0.75-0.87) ,0.001 1,116.8 1,212.2 0.91 (0.75-1.11) 0.4
Cause-specific
Cardiovascular disease 190.7 273.7 0.69 (0.62-0.78) ,0.001 195.5 272.6 0.72 (0.54-0.95) 0.02
Infection 385.9 457.3 0.86 (0.77-0.95) 0.003 433.4 395.2 1.11 (0.85-1.47) 0.4
Dialysis access dysfunction 32.5 48.6 0.66 (0.53-0.83) ,0.001 31.4 45.6 0.62 (0.29-1.33) 0.2
Other cause 418.2 487.3 0.85 (0.77-0.93) ,0.001 456.5 498.7 0.90 (0.68-1.19) 0.5
On-treatment
Admissions (per 100 patient-y)
All-cause 166.3 195.3 0.86 (0.83-0.89) ,0.001 177.0 176.4 0.94 (0.85-1.03) 0.2
Cause-specific
Cardiovascular disease 36.9 45.7 0.85 (0.79-0.92) ,0.001 38.5 45.3 0.89 (0.73-1.08) 0.2
Infection 51.1 62.4 0.82 (0.77-0.87) ,0.001 55.4 49.0 1.05 (0.88-1.25) 0.6
Dialysis access dysfunction 9.6 9.1 1.03 (0.89-1.20) 0.7 7.6 8.4 0.89 (0.57-1.38) 0.6
Other cause 68.8 78.1 0.90 (0.85-0.95) ,0.001 75.5 73.6 0.97 (0.83-1.12) 0.6
Hospital days (per 100 patient-y)
All-cause 944.8 1,213.7 0.78 (0.72-0.84) ,0.001 1,089.0 1,100.7 0.97 (0.78-1.20) 0.8
Cause-specific
Cardiovascular disease 161.7 262.8 0.61 (0.53-0.71) ,0.001 170.8 245.4 0.69 (0.50-0.96) 0.03
Infection 393.7 458.5 0.86 (0.77-0.96) 0.007 446.6 348.9 1.28 (0.95-1.73) 0.1
Dialysis access dysfunction 32.0 46.6 0.70 (0.54-0.90) 0.005 23.9 49.1 0.50 (0.24-1.02) 0.06
Other cause 357.4 445.8 0.80 (0.71-0.90) ,0.001 447.7 457.4 0.95 (0.70-1.30) 0.8
Note: Referent: matched PD patients.
Abbreviations: CI, confidence interval; ESRD, end-stage renal disease; HHD, home hemodialysis; PD, peritoneal dialysis; RR, rate
ratio.
aHazard ratio from Prentice-Williams-Peterson regression of admissions and relative rate from Poisson regression of days.
Weinhandl, Gilbertson, and CollinsConversely, PD may negatively alter the risk for
cardiovascular morbidity. Fluid overload is a highly
likely complication in PD patients28 and the causes are
multifactorial, including poor adherence to ﬂuid intake
restriction, low efﬂuent drain volume, and high
transporter status.29 A likely important etiologic factor
for the incidence of ﬂuid overload on PD is loss of
residual kidney function.30 We lacked data for urine
output at or after ESRD onset. However, it is inter-
esting that daily HHD was most strongly associated
with lower risk for death in patients who initiated
home dialysis therapy after more than 6 months since
ESRD onset, but was not associated with risk for death
in relatively new dialysis patients, except with
elapsing follow-up, during which time residual kidney
function plausibly declined and the association of
daily HHD with lower risk for death gradually man-
ifested. Residual kidney function and the anticipated
rate of loss of function may be important to consider106in the decision to prescribe either daily HHD or PD.
Nevertheless, every comparison of cardiovascular-
related mortality or hospitalization risk in our study
favored daily HHD, from 7% to 39%; even in the
subset of new dialysis patients, rates of hospital days
due to cardiovascular disease were signiﬁcantly lower
with daily HHD. This concurs with a recent analysis
by Suri et al,19 who compared admissions with daily
HHD and PD from 1 US dialysis provider.
Infection is an ongoing threat to the successful
execution of both daily HHD and PD. We previously
reported that daily HHD patients had signiﬁcantly
higher rates of hospitalization due to infection
generally and sepsis, metastatic infections of the heart
and bone, and vascular access infection speciﬁcally,
relative to matched in-center hemodialysis patients.22
Mechanisms that may underlie this excess risk
include poor hygiene in the home setting,31 late
reporting of symptoms of infection,31 limited accessAm J Kidney Dis. 2016;67(1):98-110
Table 4. RRs of Type-Specific Hospital Admissions for Daily Home Hemodialysis Patients in Intention-to-Treat and
On-Treatment Analyses
Intention-to-Treat On-Treatment
RRa (95% CI) P %b RRa (95% CI) P %b
Cardiovascular disease
Arrhythmia 1.04 (0.85-1.27) 0.7 6.4 1.24 (0.97-1.57) 0.08 5.6
Cerebrovascular disease 0.63 (0.50-0.79) ,0.001 9.5 0.61 (0.46-0.80) ,0.001 10.3
Heart failure, fluid overload, and cardiomyopathy 0.82 (0.72-0.93) 0.003 17.7 0.77 (0.66-0.88) 0.005 16.5
Hypertensive disease 0.78 (0.69-0.88) ,0.001 21.8 0.79 (0.68-0.93) ,0.001 16.7
Ischemic heart disease 1.06 (0.91-1.24) 0.4 14.3 1.13 (0.94-1.36) 0.2 16.0
Peripheral arterial disease 0.73 (0.63-0.84) ,0.001 25.1 0.67 (0.56-0.79) ,0.001 29.5
Other cardiovascular disease 1.28 (0.96-1.71) 0.09 5.2 1.39 (0.98-1.97) 0.07 5.4
Infection
Bacteremia and sepsis 1.18 (1.04-1.33) 0.007 19.2 1.22 (1.05-1.42) 0.01 18.3
Cardiac infection 3.12 (1.93-5.04) ,0.001 1.5 4.33 (2.37-7.91) ,0.001 1.1
Human immunodeficiency virus 1.08 (0.49-2.35) 0.9 0.3 1.09 (0.45-2.65) 0.9 0.4
Osteomyelitis 1.42 (0.90-2.23) 0.1 2.1 1.93 (1.00-3.74) 0.05 1.2
Respiratory infection 1.08 (0.94-1.23) 0.3 12.7 1.23 (1.04-1.46) 0.02 9.7
Urinary tract infection 0.98 (0.74-1.30) 0.9 2.8 0.86 (0.59-1.25) 0.4 2.5
Dialysis access infection, including peritonitis 0.64 (0.58-0.70) ,0.001 42.6 0.56 (0.50-0.62) ,0.001 48.1
Other infection 0.82 (0.73-0.93) 0.001 18.8 0.74 (0.64-0.85) ,0.001 18.7
Note: Referent: matched PD patients.
Abbreviations: CI, confidence interval; RR, rate ratio.
aHazard ratio from Prentice-Williams-Peterson regression.
bPercentage of cause-specific admissions in cohort of matched peritoneal dialysis patients.
Outcomes of Daily HHD Versus PDto systemic antibiotics, and difﬁculty with buttonhole
cannulation.32 In PD patients, catheter exit-site in-
fections and peritonitis are common. The USRDS
reported that rates of hospitalization with a principal
or secondary discharge diagnosis of peritonitis
declined very little in successive cohorts of prevalent0 1 2 3 4
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Figure 3. Cumulative incidence estimates of technique failure in
duration less than 6 months on the index date. Abbreviations: DHHD
Am J Kidney Dis. 2016;67(1):98-110PD patients for 2000 to 2010.33 We found a mixed
set of associations in the current study. On the one
hand, hospital admissions for dialysis access infec-
tion, including peritonitis, occurred less frequently
in daily HHD than in PD patients. On the other
hand, hospital admissions for sepsis and metastaticFollow−up time (years)
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(A) all patients and (B) the subset with end-stage renal disease
, daily home hemodialysis; PD, peritoneal dialysis.
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Weinhandl, Gilbertson, and Collinsinfections of the heart and bone occurred more
frequently in daily HHD than in PD patients. These
associations suggest that access infections necessi-
tating hospitalization may be less likely with daily
HHD than with PD, but that repeated access to the
vasculature, instead of the peritoneal cavity, places
daily HHD patients at higher risk for bloodstream
infection. Regarding ESRD duration, we found het-
erogeneity in relative risks of infection-related
mortality and hospitalization, such that risks for
patients who initiated daily HHD therapy soon after
ESRD onset were similar to risks for matched PD
patients. We lacked serial data about vascular access
type in daily HHD patients. Plausibly, more patients
who initiated daily HHD therapy within 6 months
versus more than 6 months after ESRD onset used a
catheter for vascular access, thereby setting the
aggregate cohort at higher risk for infection-related
morbidity. Current vascular access type, likelihood
of ﬁstula maturation, and anticipated access patency
may be important factors to consider in the decision
to prescribe either daily HHD or PD.
Prescription considerations aside, we found that
daily HHD and matched PD patients who initiated
home dialysis therapy soon after ESRD onset had
similar hazards of all-cause mortality and all-cause
hospitalization despite possibilities of relatively
low residual kidney function and relatively high
catheter reliance in daily HHD patients. Further-
more, in a study of all-cause mortality among inci-
dent dialysis patients in Australia and New Zealand,
HHD was associated with better survival than PD.20
These observations challenge the contention that PD
is clinically superior to daily HHD for all new
dialysis patients and shift the focus to other con-
siderations. Technique failure was signiﬁcantly less
likely with daily HHD than with PD. For daily HHD
patients, psychosocial burden is an important cause
of technique failure.34 For PD patients, comorbid
complications (eg, peritonitis) are more common
causes of technique failure.35 The apparent differ-
ence in risk may be mediated because most US
dialysis providers require HHD patients to have a
care partner, whereas PD patients are generally not
required to have a partner. The support provided by
another person may directly improve home dialysis
persistence for daily HHD patients. Nevertheless,
PD patients who revert to in-center hemodialysis
tend to be costly due to acutely poor health and
temporary reliance on a catheter for vascular ac-
cess.36 Although training for PD therapy is less
resource intensive than training for HHD, future
excess costs attributable to higher risk for technique
failure with PD may outweigh present cost savings
attributable to PD training; the total cost calculus
of daily HHD versus PD for providers and payers108alike merits further investigation. Daily HHD was
also associated with decreased risk for death due
to cachexia or dialysis therapy withdrawal, both
here and in another study of daily HHD versus
in-center hemodialysis.37 With observations of im-
proved quality of life after daily HHD initiation,38
these data suggest that daily HHD may offer to-
lerability advantages over both PD and in-center
hemodialysis.
This study has important limitations. First, it is
observational. Matching is unlikely to reduce con-
founding attributable to unmeasured factors. Residual
differences in biochemistry, residual kidney function,
and peripheral vascular health may underlie observed
relative risks. Some patients in the study cohort may
have been prescribed PD as a salvage therapy late in
the natural history of ESRD due to failure to thrive on
hemodialysis therapy or multiple failed accesses.
Second, we lacked data regarding dialysis frequency,
duration, and dose in daily HHD patients and fre-
quency and solution in PD patients. We did not
distinguish between continuous ambulatory and
continuous cycling PD. Third, we used diagnosis
codes to classify admissions. Principal codes on
inpatient claims may not accurately reﬂect morbidity.
Fourth, our results should be interpreted in the context
of the NxStage System One, a low dialysate volume
machine that is one among several devices used
for HHD.
In conclusion, we found that daily HHD patients
had signiﬁcantly lower risks for mortality, hospi-
talization, and technique failure than matched
PD patients. However, in the subset of patients
who initiated home dialysis therapy shortly after
ESRD onset, we found that risks for mortality and
hospitalization were similar for daily HHD patients
and PD patients. Further studies are needed to
replicate ﬁndings, particularly among incident pa-
tients with ESRD who begin on home dialysis
therapy. Meanwhile, daily HHD may be a viable
ﬁrst modality for patients who choose to dialyze
at home and may keep patients at home longer
than PD does.
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